AmerisourceBergen merges pharma packing units
pharmafile | June 12, 2012 | News story | Manufacturing and Production |Â Â AmericsourceBergen, Anderson Packaging, TaylorÂ
Brecon Pharmaceuticals of the UK has officially joined forces with US firm Anderson Packaging to form a new pharma-focused packaging specialist called AndersonBrecon.
The two companies have been working alongside each other since 2006 as units of drug distribution and wholesale giant AmerisourceBergen, but will now align their operations into a single, end-to-end pharma packaging firm.
The combined company has 12 facilities, a presence in 100 countries around the world and around 1,500 staff, said AndersonBrecon, which will operate as a division of AmerisourceBergen Consulting Services (ABCS).
The division is the largest contract packager in the US with one million sq. ft. of facility capacity, and works with 14 of the top 15 pharmaceutical manufacturers. The acquisition of Brecon in a $28 million deal in 2006 gave the group a bigger position in clinical trial packaging, which is one of the fastest growing in the pharma packaging market.
The decision ties in with the trend among outsourcing companies to pursue global scale in order to help secure strategic-level contracts with big pharma companies, and comes on the end of a major period of restructuring at AmerisourceBergen.
Last year, the $80 billion company realigned its business units across three main areas; AmerisourceBergen Drug Corporation (ABDC) focusing on high volume pharmaceutical product distribution; AmerisourceBergen Specialty Group (ABSG) covering speciality pharma such as oncology drugs and plasma products; and ABCS which along with contract and clinical packaging offers patient services and strategic consulting.
“Over the last four years, the Anderson and Brecon teams worked closely together to build the foundation for a truly global healthcare packaging partner,” said Peyton Howell, president of ABCS.
“Moving to a more global organisation will better position us to offer our customers a more integrated approach for the global launch of pharmaceutical products, helping to accelerate speed-to-market and product success,” he added.
Phil Taylor
Related Content
Novo Nordisk unveils plans for $100m API plant
Novo Nordisk says it will invest around $100m in a new pilot facility to make …
UK cancer death rate could be halved by 2030
British cancer deaths could drop 50% by 2030 if early diagnosis and improved treatment policies …
FDA and EMA team up for generic drug inspections
The regulatory authorities in the US and EU have taken another step towards harmonisation by …
